Datameds AI, Inc. is a US-listed company in the health care technology industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
~$1.2
Price-to-sales vs peers
Base case. Range ~$1.2–$12. Sales per share times peers' typical price-to-sales; used only when earnings are negative.
No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.
Datameds AI, Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Revenue for the twelve months to June 2026 was $8m. Free-cash-flow margin fell to -200.1% from -21.0% a year earlier. Operating margin narrowed to -875.7% from -115.2%. It passes 0 of our 5 financial-health checks. Our price-to-sales vs peers value is $1.99 a share, against a share price of $2.06.
Source: 10-Q filed August 17, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Datameds AI, Inc.'s trailing-twelve-month revenue fell 78.2% year on year, with a free-cash-flow margin of -200.1%.
Current signal Revenue growth decelerating: TTM revenue growth slowed to -78.2% (-26.6pp vs the prior quarter).
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Nothing in Datameds AI, Inc.'s latest figures clears our strength thresholds.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
We value Datameds AI, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.1%: the 10-year Treasury yield (4.9%) plus a beta of 1.15 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: book value or earnings not available |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | ~$1.2 ~$1.7–$12 | Included, half weight |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$1.2 ~$1.2–$12 | 1 model |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Datameds AI, Inc. with Health Care Technology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2025 |
|---|---|
| Share price | $20.00 |
| Market value | $1.4bn |
| + Net debt (− = net cash) | $23m |
| Enterprise value | $1.4bn |
| Multiples | |
| Price / sales | 60.8x |
| Price / earnings | — |
| Price / free cash flow | — |
| EV / EBITDA | — |
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
No analyst estimates are published for Datameds AI, Inc.: too few analysts cover it.
| Calendar year | 2026 to date |
|---|---|
| Return | |
| MEDS | −91% |
| Industry peers (median) | −26% |
| S&P 500 | +11% |
| Months that ended higher | |
| MEDS | 18% |
| S&P 500 | 46% |
| Largest fall from a high during the year | |
| MEDS | −96% |
| S&P 500 | −9% |
Worst fall since February 21, 2025: 100% from March 21, 2025 to September 9, 2026. Getting back needed a 29042% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 18, 2026 | −4.0% | −0.5% | −8.7% | +211.4% |
| May 19, 2026 | −25.9% | +0.4% | −63.7% | −61.0% |
| November 20, 2025 | −13.6% | −0.5% | +3.6% | −19.3% |
| August 22, 2025 | +116.6% | +1.1% | +62.5% | +34.7% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY25 Q1 | $29M |
| FY25 Q2 | $36.7M |
| FY25 Q3 | $34.1M |
| FY25 Q4 | $23.3M |
| FY26 Q1 | $14M |
| FY26 Q2 | $8M |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY25 Q1 | -129.0% |
| FY25 Q2 | -115.2% |
| FY25 Q3 | -211.7% |
| FY25 Q4 | -401.7% |
| FY26 Q1 | -487.5% |
| FY26 Q2 | -875.7% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY25 Q1 | -15.6% |
| FY25 Q2 | -21.0% |
| FY25 Q3 | -30.1% |
| FY25 Q4 | -60.3% |
| FY26 Q1 | -111.8% |
| FY26 Q2 | -200.1% |
| Fiscal year | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|
| Income | |||
| Revenue | 18 | 23 | 8 |
| Gross profit | 2 | −6 | −7 |
| EBITDA | −5 | −91 | −68 |
| Operating income | −6 | −94 | −70 |
| Net income | −7 | −101 | −88 |
| Diluted EPS | −$0.15 | −$1.43 | — |
| Growth (year on year) | |||
| Revenue | — | +28.7% | −78.2% |
| Margins | |||
| Gross margin | 9.7% | −27.5% | −90.6% |
| EBITDA margin | −27.7% | −387.9% | −846.8% |
| Operating margin | −33.9% | −401.7% | −875.7% |
| Net margin | −37.8% | −433.9% | <−999% |
| Cash flow | |||
| Cash from operations | −1 | −11 | −14 |
| Stock-based pay | 1 | 55 | 29 |
| Balance sheet | |||
| Cash | 1 | 0 | 2 |
| Total debt | 23 | 23 | 41 |
| Net debt (negative = net cash) | 22 | 23 | 38 |
| Diluted shares | 47m | 71m | — |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 6 | 12 | 11 | 8 | 3 | 2 | 2 | 2 |
| Gross profit | 1 | 1 | 1 | 1 | 0 | −8 | 0 | 0 |
| EBITDA | −1 | −3 | −31 | −5 | −31 | −25 | −6 | −7 |
| Operating income | −2 | −4 | −31 | −6 | −32 | −25 | −6 | −7 |
| Net income | −2 | −4 | −32 | −7 | −34 | −28 | −8 | −18 |
| Diluted EPS | −$2.00 | −$0.10 | −$0.62 | −$5.40 | −$23.00 | −$0.25 | −$3.50 | −$7.13 |
| Growth (year on year) | ||||||||
| Revenue | — | — | — | +>999% | −46.9% | −86.5% | −85.6% | −77.2% |
| Margins | ||||||||
| Gross margin | 9.2% | 10.1% | 6.4% | 6.5% | 7.7% | −470.2% | 10.9% | 10.2% |
| EBITDA margin | −22.5% | −25.0% | −281.2% | −60.3% | <−999% | <−999% | −362.8% | −392.6% |
| Operating margin | −30.8% | −30.2% | −288.6% | −70.6% | <−999% | <−999% | −385.7% | −412.7% |
| Net margin | −32.9% | −34.9% | −298.5% | −85.6% | <−999% | <−999% | −496.5% | <−999% |
| Cash flow | ||||||||
| Cash from operations | 1 | −3 | −1 | −2 | −1 | −6 | −3 | −3 |
| Stock-based pay | — | — | 28 | 1 | 26 | 0 | 1 | 1 |
| Last 12 months unless stated | MEDS | MNDR | DRIO | WORX | HCTI | AIFF | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $8m | $8m | $21m | $3m | $26m | $2m | $262m |
| Revenue growth, last 12 months | −78.2% | 1.2% | −22.6% | 3.1% | 116.4% | 320.3% | 8.6% |
| Revenue growth, 3-year average | — | — | −7.6% | −9.9% | −14.9% | −41.3% | 0.8% |
| Revenue growth, latest quarter | −77.2% | — | −3.6% | 3.4% | 158.4% | 71.9% | 7.4% |
| Gross margin | −90.6% | 21.2% | 58.2% | 44.7% | 21.5% | 44.6% | 58.2% |
| Operating margin | −875.7% | — | −151.6% | −20.1% | −57.4% | −508.1% | −18.5% |
| Operating margin, 3-year average | — | — | −213.6% | −36.9% | −40.6% | <−999% | −18.8% |
| Net margin | <−999% | −41.2% | −169.9% | −80.5% | −66.3% | −506.2% | −18.0% |
| Cash from operations / revenue | −171.2% | −19.7% | −120.7% | −25.5% | −62.4% | −388.6% | 6.1% |
| Free-cash-flow margin | −200.1% | −19.7% | −121.3% | −86.6% | −62.4% | −388.6% | 3.9% |
| Free-cash-flow margin, 3-year average | — | — | −144.7% | — | −44.7% | <−999% | 8.2% |
| Stock pay / revenue | 356.9% | 19.9% | 33.6% | 9.5% | 3.2% | 62.0% | 9.6% |
| Change in share count | — | 265.5% | 25.9% | 207.2% | — | 27.7% | 2.9% |
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $21.9M | 93.7% | ▲ 23.8% |
| Pharmacy Retail Sales | $865,695 | 3.7% | ▲ 145.7% |
| Third Party Logistics Services | $603,417 | 2.6% | ▲ 463.9% |
From Datameds AI, Inc.'s 10-K filed March 20, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Jane Street Group, LLC | $63,649 | 21K | 39.6% | — |
| Geode Capital Management, LLC | $38,647 | 12K | 24.1% | — |
| Vanguard Capital Management LLC | $34,364 | 11K | 21.4% | — |
| Vanguard Fiduciary Trust Co | $19,192 | 6K | 11.9% | — |
| Barclays PLC | $2,241 | 1K | 1.4% | — |
| Tower Research Capital LLC (TRC) | $2,102 | 1K | 1.3% | — |
| Fortitude Family Office, LLC | $366 | 0K | 0.2% | — |
| Integrated Wealth Concepts LLC | $78 | 0K | 0.0% | — |
| Global Retirement Partners, LLC | $6 | 0K | 0.0% | — |
| Danske Bank A/S | $3 | 0K | 0.0% | — |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Datameds AI, Inc.'s complete shareholder register. Values are as reported by the filers .
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around November 17, 2026 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
